GenSight advances LUMEVOQ manufacturing transfer to Catalent

GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access programmes. The company also reported receiving revenue under the French access programme. These developments do not constitute full marketing authorisation for the therapy.

Sources:

• GenSight Biologics — operational update